The role of carfilzomib in relapsed/refractory multiple myeloma

被引：15

作者：

Yee, Andrew J. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷

关键词：

carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;

D O I：

10.1177/20406207211019612

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.

引用

页数：13

共 50 条

[31] Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease [J].

Zhou, Xiang ;

Fluechter, Patricia ;

Nickel, Katharina ;

Meckel, Katharina ;

Messerschmidt, Janin ;

Boeckle, David ;

Knorz, Sebastian ;

Steinhardt, Maximilian Johannes ;

Krummenast, Franziska ;

Danhof, Sophia ;

Einsele, Hermann ;

Kortuem, K. Martin ;

Rasche, Leo .

CANCERS, 2020, 12 (04)

[32] Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma [J].

Stewart, A. Keith ;

Rajkumar, S. Vincent ;

Dimopoulos, Meletios A. ;

Masszi, Tamas ;

Spicka, Ivan ;

Oriol, Albert ;

Hajek, Roman ;

Rosinol, Laura ;

Siegel, David S. ;

Mihaylov, Georgi G. ;

Goranova-Marinova, Vesselina ;

Rajnics, Peter ;

Suvorov, Aleksandr ;

Niesvizky, Ruben ;

Jakubowiak, Andrzej J. ;

San-Miguel, Jesus F. ;

Ludwig, Heinz ;

Wang, Michael ;

Maisnar, Vladimr ;

Minarik, Jiri ;

Bensinger, William I. ;

Mateos, Maria-Victoria ;

Ben-Yehuda, Dina ;

Kukreti, Vishal ;

Zojwalla, Naseem ;

Tonda, Margaret E. ;

Yang, Xinqun ;

Xing, Biao ;

Moreau, Philippe ;

Palumbo, Antonio .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02) :142-152

[33] Current strategies for treatment of relapsed/refractory multiple myeloma [J].

Laubach, Jacob P. ;

Voorhees, Peter M. ;

Hassoun, Hani ;

Jakubowiak, Andrzej ;

Lonial, Sagar ;

Richardson, Paul G. .

EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) :97-111

[34] Relapsed and Refractory Multiple Myeloma New Therapeutic Strategies [J].

Gentili, Silvia ;

Lonial, Sagar .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (05) :861-+

[35] Management of Relapsed and Refractory Multiple Myeloma: Recent advances [J].

Rathnam, Krishnakumar ;

Saju, S. V. V. ;

Honey, Susan Raju .

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2022, 43 (06) :458-472

[36] The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma [J].

Comeau, Jill M. ;

Kelly, Katherine ;

Jean, Gary W. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (02) :55-66

[37] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design [J].

Moreau, Philippe ;

Dimopoulos, Meletios A. ;

Yong, Kwee ;

Mikhael, Joseph ;

Risse, Marie-Laure ;

Asset, Gaelle ;

Martin, Thomas .

FUTURE ONCOLOGY, 2020, 16 (02) :4347-4358

[38] Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma [J].

Leleu, Xavier ;

Martin, Thomas G. ;

Einsele, Hermann ;

Lyons, Roger M. ;

Durie, Brian G. M. ;

Iskander, Karim S. ;

Ailawadhi, Sikander .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01) :9-22

[39] Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib [J].

Nooka, Ajay ;

Gleason, Charise ;

Casbourne, Daniela ;

Lonial, Sagar .

BIOLOGICS-TARGETS & THERAPY, 2013, 7 :13-32

[40] Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma [J].

Gupta, Vikas A. ;

Nooka, Ajay K. ;

Lonial, Sagar ;

Boise, Lawrence H. .

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2013, 3 :41-51

← 1 2 3 4 5 →